Highlights

  • Optiscan shares rose 2.33% on 20 May 2026, following the release of latest update.
  • Optiscan Imaging received a FY25 R&D tax refund of AUD 1.69 million.
  • The refund was received under the Australian Government’s R&D tax incentive program.
  • The FY25 refund outcome was broadly in line with company expectations.
  • Optiscan said the refund supports ongoing Investment in R&D and clinical programs.
  • The company continues advancing commercialisation initiatives across its imaging platform.

Optiscan Imaging Ltd (ASX:OIL) shares traded 2.33% higher to AUD 0.11 during the afternoon session on 20 May 2026 after the company announced it had received a FY25 Research and Development (R&D) tax refund worth AUD 1.69 million. The latest funding update appeared to draw investor attention as the company continues progressing clinical development activities and broader commercialisation initiatives across its imaging technology platform. Despite today’s gain, the stock remains down 8.33% over the past year.

The refund forms part of the Australian Federal Government’s R&D tax incentive program, which provides eligible companies conducting qualifying research and development activities with refundable tax offsets of up to 43.5%. According to Optiscan, the FY25 refund totalled AUD 1,693,714 and was broadly consistent with the company’s expectations.

Company Overview

Optiscan Imaging Ltd is an Australian medical technology company focused on confocal laser endomicroscopy imaging systems.

The company develops imaging hardware and software solutions aimed at digital pathology, diagnostics, precision surgery and life sciences applications.

Its technology enables live optical biopsy imaging at the cellular level and is designed to support real-time clinical decision-making.

Optiscan’s products target applications across surgery, diagnostics, pre-clinical research and digital healthcare workflows.

The company continues advancing commercialisation activities while investing in clinical development and product expansion initiatives.

FY25 Refund Remains Elevated Relative to Prior Years

While the FY25 refund was slightly below the AUD 1,775,733 received in FY24, Optiscan noted that the latest outcome continues to remain elevated relative to earlier years. The company linked this to the successful Advance and Overseas Finding application secured during FY24.

That application allows eligible overseas R&D expenditure to qualify under the Australian Government’s R&D tax incentive framework, expanding the range of research costs that may be claimed by the company.

Management indicated that the refund contributes to funding support for ongoing research programs and clinical studies as Optiscan continues developing its imaging technologies for broader medical applications.

The company stated that the R&D incentive remains an important component in supporting innovation activities and continued product development.

Company Highlights Ongoing Clinical and Commercialisation Focus

Optiscan Chief Executive Officer and Managing Director Dr Camile Farah said the refund reinforces the company’s funding position while supporting continued investment across key research and development programs.

According to management commentary, the company remains focused on advancing clinical studies and progressing toward wider commercialisation of its technology platform.

The company also acknowledged the role of government-backed innovation initiatives in supporting Australian technology developers working on globally relevant healthcare solutions.

Optiscan’s broader strategy remains centred around expanding the commercial and clinical relevance of its imaging technologies across diagnostics, surgery and life sciences applications.

Focus on Digital Pathology and Precision Surgery

Optiscan Imaging Ltd operates in the medical imaging sector and focuses on confocal laser endomicroscopy technology, which enables real-time imaging at the cellular level.

The company has developed a suite of hardware and software products designed for digital pathology and precision surgery applications. Its technology allows clinicians and researchers to generate live optical biopsy images during procedures without requiring destructive tissue removal methods.

Optiscan stated that its miniaturised digital endomicroscopes provide imaging resolution significantly higher than traditional CT and MRI technologies.

Using what the company describes as a “tissue contact” imaging method, the platform is designed to produce high-resolution pathology images for cancer diagnosis, surgical guidance and pre-clinical research applications.

The technology is aimed at supporting earlier disease detection, precision treatment and improved clinical decision-making through live imaging capabilities.

Broader Market Opportunity Remains a Key Focus

The company believes its addressable market extends beyond traditional pathology and surgery applications into broader digital health and robotic surgery segments.

As healthcare systems continue incorporating digital workflows and image-guided technologies, Optiscan is positioning its platform across multiple clinical and research settings.

According to the company, increasing Demand for digital health technologies and precision-based treatment approaches may support wider adoption opportunities over time.

The company is also seeking to bridge workflow gaps between surgery and pathology by enabling near real-time imaging and tissue assessment during procedures.

Optiscan’s product suite continues to expand as the company progresses both hardware and software development initiatives.

Why the R&D Incentive Matters for Emerging MedTech Companies

For emerging medical technology companies, R&D incentives can play an important role in supporting product development cycles, particularly where clinical validation, regulatory processes and technology refinement may require ongoing investment over multiple years.

In Optiscan’s case, the FY25 refund provides additional non-dilutive funding support that may assist with continued investment into clinical studies and innovation programs.

The Australian Government’s R&D tax incentive program is designed to encourage eligible companies to undertake research and development activities domestically while supporting commercialisation pathways for innovation-focused businesses.

The inclusion of eligible overseas expenditure under the Advance and Overseas Finding framework can also provide flexibility for companies conducting international development or collaborative research activities.

Commercial Stage Positioning

Unlike early-stage concept companies, Optiscan describes itself as a commercial-stage medical technology company.

Its focus includes the development of digital pathology and surgical imaging solutions capable of integration into healthcare environments ranging from operating theatres to research laboratories.

The company’s imaging platform is intended to support applications in diagnostics, precision surgery and life sciences research.

Management continues to position the Business around long-term adoption opportunities linked to real-time imaging and digital healthcare workflows.

Medical Imaging and Digital Health Trends

The broader healthcare sector has increasingly focused on technologies that may improve procedural efficiency, diagnostic precision and patient outcomes.

Digital pathology, image-guided surgery and robotic-assisted procedures continue attracting investment and research attention globally as healthcare systems seek to improve workflow integration and clinical visibility.

Optiscan’s technology platform is designed to operate within these developing trends through real-time, non-destructive imaging capabilities at the cellular level.

The company has previously highlighted opportunities linked to the expansion of digital health ecosystems and increasing demand for precision-focused surgical technologies.

Funding Position and Development Pipeline

While the latest announcement focused specifically on the R&D tax refund, management commentary suggested that the additional funding support is expected to contribute toward ongoing development programs.

The company indicated that the refund supports continued progress across its innovation pipeline and clinical activities as it advances commercialisation efforts.

Optiscan did not announce additional financial guidance alongside the update, though the company reiterated the strategic importance of ongoing research investment.

The FY25 refund outcome was also described as being broadly aligned with management expectations.

What This Means for Investors?

Optiscan’s latest update highlighted the receipt of AUD 1.69 million under the Australian Government’s R&D tax incentive program, providing additional funding support for the company’s research and clinical development activities.

The market appeared to respond positively to the announcement, with shares moving higher during the afternoon session following the release.

The update also reinforced management’s focus on advancing commercialisation efforts while continuing investment across its medical imaging technology platform.

Investors are likely to continue monitoring Optiscan’s progress in clinical studies, commercial partnerships, product development initiatives and broader adoption opportunities within digital pathology and precision surgery markets.